Cyclovirobuxine D

Cyclovirobuxine D (CVB-D) is the main active component of the traditional Chinese medicine Buxus microphylla. Cyclovirobuxine D induces autophagy and attenuates the phosphorylation of Akt and mTOR[1]. Cyclovirobuxine D inhibits cell proliferation of gastric cancer cells through suppression of cell cycle progression and inducement of mitochondria-mediated apoptosis[2]. Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction[3].

Product Specifications

CAS Number

[860-79-7]

UNSPSC

12352211

Hazard Statement

H301

Target

Akt; Apoptosis; Autophagy; mTOR

Type

Natural Products

Related Pathways

Apoptosis; Autophagy; PI3K/Akt/mTOR

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/cyclovirobuxine-d.html

Purity

99.70

Solubility

Ethanol : 13 mg/mL (ultrasonic)

Smiles

C[C@H](NC)[C@@]1([H])[C@H](O)C[C@@]2(C)[C@]3([H])CC[C@@]4([H])C(C)(C)[C@@H](NC)CC[C@]4(C5)[C@]35CC[C@@]21C

Molecular Formula

C26H46N2O

Molecular Weight

402.66

Precautions

H301

References & Citations

[1]Lu J, et al. Cyclovirobuxine D induces autophagy-associated cell death via the Akt/mTOR pathway in MCF-7 human breast cancer cells. J Pharmacol Sci. 2014;125 (1) :74-82. Epub 2014 Apr 24.|[2]Wu J, et al. Cyclovirobuxine D Inhibits Cell Proliferation and Induces Mitochondria-Mediated Apoptosis in Human Gastric Cancer Cells. Molecules. 2015 Nov 19;20 (11) :20659-68.|[3]Yu B, et al. Beneficial effect of Cyclovirobuxine D on heart failure rats following myocardial infarction. Fitoterapia. 2011 Sep;82 (6) :868-77.